These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 24352648

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
    Morris EJ, Jha S, Restaino CR, Dayananth P, Zhu H, Cooper A, Carr D, Deng Y, Jin W, Black S, Long B, Liu J, Dinunzio E, Windsor W, Zhang R, Zhao S, Angagaw MH, Pinheiro EM, Desai J, Xiao L, Shipps G, Hruza A, Wang J, Kelly J, Paliwal S, Gao X, Babu BS, Zhu L, Daublain P, Zhang L, Lutterbach BA, Pelletier MR, Philippar U, Siliphaivanh P, Witter D, Kirschmeier P, Bishop WR, Hicklin D, Gilliland DG, Jayaraman L, Zawel L, Fawell S, Samatar AA.
    Cancer Discov; 2013 Jul; 3(7):742-50. PubMed ID: 23614898
    [Abstract] [Full Text] [Related]

  • 3. BRAF inhibitors in cancer therapy.
    Hertzman Johansson C, Egyhazi Brage S.
    Pharmacol Ther; 2014 May; 142(2):176-82. PubMed ID: 24325952
    [Abstract] [Full Text] [Related]

  • 4. Therapeutic strategies for inhibiting oncogenic BRAF signaling.
    Halilovic E, Solit DB.
    Curr Opin Pharmacol; 2008 Aug; 8(4):419-26. PubMed ID: 18644254
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Resistance to MEK inhibitors: should we co-target upstream?
    Poulikakos PI, Solit DB.
    Sci Signal; 2011 Mar 29; 4(166):pe16. PubMed ID: 21447797
    [Abstract] [Full Text] [Related]

  • 7. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
    Wang AX, Qi XY.
    IUBMB Life; 2013 Sep 29; 65(9):748-58. PubMed ID: 23893853
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
    Liu D, Hu S, Hou P, Jiang D, Condouris S, Xing M.
    Clin Cancer Res; 2007 Feb 15; 13(4):1341-9. PubMed ID: 17317846
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Targeting BRAF in melanoma: biological and clinical challenges.
    Mandalà M, Voit C.
    Crit Rev Oncol Hematol; 2013 Sep 15; 87(3):239-55. PubMed ID: 23415641
    [Abstract] [Full Text] [Related]

  • 15. ERK inhibition overcomes acquired resistance to MEK inhibitors.
    Hatzivassiliou G, Liu B, O'Brien C, Spoerke JM, Hoeflich KP, Haverty PM, Soriano R, Forrest WF, Heldens S, Chen H, Toy K, Ha C, Zhou W, Song K, Friedman LS, Amler LC, Hampton GM, Moffat J, Belvin M, Lackner MR.
    Mol Cancer Ther; 2012 May 15; 11(5):1143-54. PubMed ID: 22402123
    [Abstract] [Full Text] [Related]

  • 16. Gatekeeper mutations mediate resistance to BRAF-targeted therapies.
    Whittaker S, Kirk R, Hayward R, Zambon A, Viros A, Cantarino N, Affolter A, Nourry A, Niculescu-Duvaz D, Springer C, Marais R.
    Sci Transl Med; 2010 Jun 09; 2(35):35ra41. PubMed ID: 20538618
    [Abstract] [Full Text] [Related]

  • 17. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A, Arita T, Tsuchiya S, Donelan J, Chouitar J, Carideo E, Galvin K, Okaniwa M, Ishikawa T, Yoshida S.
    Cancer Res; 2013 Dec 01; 73(23):7043-55. PubMed ID: 24121489
    [Abstract] [Full Text] [Related]

  • 18. BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.
    Klempner SJ, Gershenhorn B, Tran P, Lee TK, Erlander MG, Gowen K, Schrock AB, Morosini D, Ross JS, Miller VA, Stephens PJ, Ou SH, Ali SM.
    Cancer Discov; 2016 Jun 01; 6(6):594-600. PubMed ID: 27048246
    [Abstract] [Full Text] [Related]

  • 19. Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations.
    Bradish JR, Montironi R, Lopez-Beltran A, Post KM, MacLennan GT, Cheng L.
    Future Oncol; 2013 Feb 01; 9(2):245-53. PubMed ID: 23414474
    [Abstract] [Full Text] [Related]

  • 20. Emerging Raf inhibitors.
    McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R, Milella M, Tafuri A, Lunghi P, Bonati A, Stivala F, Nicoletti F, Libra M, Martelli AM, Montalto G, Cervello M.
    Expert Opin Emerg Drugs; 2009 Dec 01; 14(4):633-48. PubMed ID: 19715444
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.